



Immune Responses to SARS-CoV-2 Infection and Vaccination

Guest Editor:

Dr. Hejun Liu

Department of Integrative
Structural and Computational
Biology, The Scripps Research
Institute, La Jolla, CA 92037, USA

Deadline for manuscript
submissions:

closed (10 July 2023)

Message from the Guest Editor

Dear Colleagues,

The COVID-19 pandemic has caused unprecedented health crises and economic losses worldwide. The SARS-CoV-2 variants evolved with escape mutations and have led to the occurrence of several COVID-19 surge peaks in the past. While the virus continues to evolve with escape mutations, understanding the immune response and antigen recognition to SARS-CoV-2 variants are urgently needed for next-generation vaccine design.

This Special Issue aims to understand viral entry mechanisms, immune responses, and antigen recognition in the context of SARS-CoV-2 variants and how broad-spectrum immunity can be archived with current knowledge. We are hoping this Special Issue provides information on developing antibody therapeutics and next-generation vaccine design.

We are pleased to invite you to present your latest research, perspectives, communications, and reviews to this Special Issue. All immune-related themes regarding SARS-CoV-2 and other related coronaviruses will be considered. However, we are particularly interested in understanding adaptive immune responses to SARS-CoV-2 infection, vaccination, and other related coronaviruses.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com